Boehringer Ingelheim has signed a deal with Enara Bio to explore the potential of what the UK biotech calls ‘dark antigens’ – antigens derived from the genomic ‘dark matter’ or the 98% of the genome that is not normally expressed, but which could yield many new targets for cancer immunotherapies.
The collaboration will focus on the discovery and validation of up to three dark antigens for lung and gastrointestinal cancers,...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
